Polymorphic forms of dasatinib

The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) - 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanedi...

Full description

Saved in:
Bibliographic Details
Main Authors BHAT, Ramakrishna Parameshwar, KALIAPPAN, Mariappan, RAGHUNADHACHETTY, Jithendrababu, PALLE, Venkata Raghavendracharyulu, REGALLA, VijayBhaskar Reddy
Format Patent
LanguageEnglish
Published 05.03.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) - 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib- butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib
Bibliography:Application Number: AU20180297710